Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Ko

Showing results (111-120 of 119) with videos related to

Pageof 12
Sort By:
You have reached the last page of results.This site can display upto 119 results.
Nature|November 11, 2016
A brain-spine interface alleviating gait deficits after spinal cord injury in primatesMarco Capogrosso, Tomislav Milekovic, David Borton, et al.
Gut|July 10, 2012
Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of the 'Arbeitsgemeinschaft Internistische Onkologie' (AIO-PK0104)Volker Heinemann, Ursula Vehling-Kaiser, Dirk Waldschmidt, et al.
Cancer Cell|April 9, 2008
Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia veraGerlinde Wernig, Michael G Kharas, Rachel Okabe, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 10, 2016
Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin or cisplatin in patients with advanced non-small-cell lung cancer (NSCLC)M Joerger, J von Pawel, S Kraff, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 23, 2011
Early prediction of nonprogression in advanced non-small-cell lung cancer treated with erlotinib by using [(18)F]fluorodeoxyglucose and [(18)F]fluorothymidine positron emission tomographyThomas Zander, Matthias Scheffler, Lucia Nogova, et al.
Progress in Neurobiology|July 26, 2015
Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's diseaseMatthieu F Bastide, Wassilios G Meissner, Barbara Picconi, et al.
Nature Medicine|November 6, 2023
A spinal cord neuroprosthesis for locomotor deficits due to Parkinson's diseaseTomislav Milekovic, Eduardo Martin Moraud, Nicolo Macellari, et al.
British Journal of Cancer|October 29, 2011
Evaluation of variation in the phosphoinositide-3-kinase catalytic subunit alpha oncogene and breast cancer riskK N Stevens, M Garcia-Closas, Z Fredericksen, et al.
Canadian Journal of Surgery. Journal Canadien De Chirurgie|April 30, 2022
Abstracts of presentations to the Annual Meetings of the Canadian Association of General Surgeons Canadian Association of Thoracic Surgeons Canadian Hepato-Pancreato-Biliary Society Canadian Society of Surgical Oncology Canadian Society of Colon and Rectal Surgeons: Victoria, BC Sept. 10-13, 2009R Nenshi, E Kennedy, N N Baxter, et al.
Pageof 12

Showing results (111-120 of 119) with videos related to

Sort By:
Pageof 12
You have reached the last page of results.This site can display upto 119 results.
Nature|November 11, 2016
A brain-spine interface alleviating gait deficits after spinal cord injury in primatesMarco Capogrosso, Tomislav Milekovic, David Borton, et al.
Gut|July 10, 2012
Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of the 'Arbeitsgemeinschaft Internistische Onkologie' (AIO-PK0104)Volker Heinemann, Ursula Vehling-Kaiser, Dirk Waldschmidt, et al.
Cancer Cell|April 9, 2008
Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia veraGerlinde Wernig, Michael G Kharas, Rachel Okabe, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 10, 2016
Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin or cisplatin in patients with advanced non-small-cell lung cancer (NSCLC)M Joerger, J von Pawel, S Kraff, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 23, 2011
Early prediction of nonprogression in advanced non-small-cell lung cancer treated with erlotinib by using [(18)F]fluorodeoxyglucose and [(18)F]fluorothymidine positron emission tomographyThomas Zander, Matthias Scheffler, Lucia Nogova, et al.
Progress in Neurobiology|July 26, 2015
Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's diseaseMatthieu F Bastide, Wassilios G Meissner, Barbara Picconi, et al.
Nature Medicine|November 6, 2023
A spinal cord neuroprosthesis for locomotor deficits due to Parkinson's diseaseTomislav Milekovic, Eduardo Martin Moraud, Nicolo Macellari, et al.
British Journal of Cancer|October 29, 2011
Evaluation of variation in the phosphoinositide-3-kinase catalytic subunit alpha oncogene and breast cancer riskK N Stevens, M Garcia-Closas, Z Fredericksen, et al.
Canadian Journal of Surgery. Journal Canadien De Chirurgie|April 30, 2022
Abstracts of presentations to the Annual Meetings of the Canadian Association of General Surgeons Canadian Association of Thoracic Surgeons Canadian Hepato-Pancreato-Biliary Society Canadian Society of Surgical Oncology Canadian Society of Colon and Rectal Surgeons: Victoria, BC Sept. 10-13, 2009R Nenshi, E Kennedy, N N Baxter, et al.
Pageof 12